A new method that allows rapid phenotyping of genetic Lp(a) glycoproteln types In large numbers of samples Is described. The method is based on sodium dodecyl sulfate gel electrophoresls of reduced serum or plasma In horizontal slab gels followed by Immunoblotting with polyclonal antl-Lp(a) llpoproteln or monoclonal anti-Lp(a) glycoproteln antibodies. Phenotyping of 194 unrelated, healthy subjects resulted In Lp(a) allele frequencies of Lp(a) B = 0.013, Lp(a) 81 = 0.032, Lp(a) S2 = 0.106, Lp(a) 33 = 0.096, Lp(a) 34 = 0.156, and Lp{a)° = 0.600, and confirmed the recently recognized association of Lp(a) glycoproteln phenotype with Lp(a) llpoproteln concentration. The new procedure is suitable for large-scale population, genetic, and epidemiologlc studies and may be Important for atherosclerotic risk assessment.
T he Lp(a) lipoprotein was first described by Berg 1 as a genetic variant of low density lipoprotein (LDL), and it was believed that this lipoprotein is inherited as an autosomal, dominant trait. After the introduction of quantitative Lp(a) measurement, it was shown that the Lp(a) lipoprotein represents a quantitative trait and that Lp(a) concentration is under polygenic control, probably with a major gene effect for high Lp(a) concentration. 2 " 5 The interest in this unusual lipoprotein was greatly stimulated by reports of an association of high levels of Lp(a) lipoprotein with atherosclerosis. 6 " 11 The Lp(a) lipoprotein is an LDL-like particle that floats in a density range of about 1.05 to 1.10 g/ml. The lipid composition is similar to that of the LDL particle, but its protein moiety contains, in addition to apo B-100, the Lp(a)-specific glycoprotein, which is linked to apo B by disulfide bonds. 12 -13> u The Lp(a) lipoprotein exhibits a density heterogeneity within and between individuals, as well as a size heterogeneity of the Lp(a)-specific glycoprotein. 1315 Recently, six different types of this Lp(a)-specific glycoprotein were resolved in our laboratory by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting. 16 Preliminary evidence suggests that Lp(a) phenotypes are genetically controlled and, moreover, are associated with Lp(a) lipoprotein concentration in plasma. 16 Hence, the interesting possibility arose that the observed association of Lp(a) lipoprotein levels with atherosclerosis might be due to differences in Lp(a) glycoprotein species, rather than to differences in the concentration of the lipoprotein. To answer this and related questions, a method that allows convenient phenotyping of a large number of samples in epidemiologic studies is needed. In this paper, we describe an improved method for Lp(a) glycoprotein phenotyping directly from serum or plasma by immunoblotting.
Methods

Electrophoretlc Procedures
Acrylamide, /V,/V'-methylene-i)/s-acrylamide (Bis) and sodium dodecyl sulfate (SDS) were purchased from BDH Chemicals (UK) and were used without further purification. The buffer substances were from Merck (FRG) and were all of analytical grade. The discontinuous buffer and gel system of Neville 17 was used with minor modifications as mentioned below. The gels (25 x 12 cm) were cast into a cassette consisting of a glass plate, onto which a PAG-Gelbond film (LKB, Bromma, Sweden) with its hydrophobic side up had been rolled, a U frame (1.5 mm thick), and a second glass plate. This second glass plate was provided with 40 slot formers by applying three layers of adhesive tape and cutting it to the dimension required ( 4 x 6 mm, 2 mm distance between the slots). The plate was treated with Repel-Silane (LKB, Bromma, Sweden).
The density of the stacking gel solution (pH = 6.14, T = 3.6%) was enlarged with glycerol (13.4%, vol/vol); the stacking gel solution was first poured into the precooled (4 C C) cassette. The resolving gel solution (pH = 9.14, T = 7%) was added immediately afterward by using the front chamber of a gradient mixer to provide a slow and even flow of the solution. This procedure produces a very even, straight border line between the two parts.
The samples were prepared by mixing 7 fi\ of serum or plasma with 50 /il of a sample buffer prepared fresh every day by mixing 2 ml of 5% SDS with 200 /il of B-mercaptoethanol and 300 fii of 1.5% Bromphenol Blue in glycerol. The well-mixed solution was boiled for 10 minutes in a water bath, and 8 /xl of this mixture was applied in the sample slots. The electrophoretic run was performed in a Multiphor II (LKB, Bromma, Sweden) cooled to 10°C. A constant power of 40 W was applied throughout the run. When the Bromphenol Blue marker had reached the end of the gel (at about 3 hours), the run was continued for an additional hour. Afterward, the gel was transferred onto a sheet of nitrocellulose membrane (BA 85,0.45 /j.m, Schleicher & Schull, FRG) and the proteins were electroblotted according to the method of Towbin et al. 18 by using the Transblot cell (Biorad, USA). The blotting was performed overnight with a constant voltage of 80 V.
The Lp(a) bands were visualized on the membrane by a double-antibody procedure. The first antibody, which was directed against Lp(a), was either a polyclonal or a monoclonal one (their production, purification, and characterization are described below). The second antibodies, goat antirabbit or goat antimouse IgG from Bioyeda, Israel, were labeled with colloidal gold (20 nm diameter) according to the method of Lin and Langenberg. 19 To increase the sensitivity of the immunoblot procedure, a physical developer consisting of silver lactate (Fluka, Switzerland) and hydroquinone (Sigma, FRG) was used when necessary. Accurate phenotyping was achieved by placing a serum with S1/S2 phenotype as an internal marker in every seventh position.
The sensitivity of the described method enables the determination of the Lp(a) glycoprotein phenotype in sera with Lp(a) lipoprotein concentrations as low as 5 mg/100 ml. This is the same sensitivity that we achieved in the electroimmunodiffusion assay that we used to determine the serum Lp(a) concentration. The Lp(a) standard serum (83.7 mg/100 ml) from Immuno (Austria) and its serial dilutions were used as standards in this assay. This standard was prepared in the manner described by Krempler et al. 20 
Production, Purification, and Characterization of Antibodies against Lp(a)
The polyclonal antibodies were raised in rabbits by using Lp(a) lipoprotein as the antigen and the immunization procedure described by Berg. 1 The antibodies were tested for specificity by reaction with human sera, LDL, and Lp(a) lipoprotein in double diffusion experiments by the Clark-Freeman technique. 21 The antisera against Lp(a) showed two precipitation lines; one was identical to LDL and the other was the same as Lp(a), but not LDL. The antisera were made specific by absorption with purified LDL and by affinity chromatography on a CN-Br-Sepharose column (Pharmacia, Sweden) to which the Lp(a)-specific glycoprotein had been coupled according to the manufacturer's description.
Monoclonal Antibodies against Lp(a)
Immunization, fusion, cell culture handling, and screening of hybridomas producing specific antibodies were performed according to standard protocols. 22 Briefly, 20 /xg of purified Lp(a) antigen mixed with complete Freund's adjuvant were injected intradermally into 8-to 10-week-old female BALB/c mice. The Lp(a)-specific glycoprotein was isolated and purified as described by Utermann et al. 16 After 3 weeks, an intradermal boost with another 10 ^ig of antigen in incomplete adjuvant and 7 days later, a last (intravenous) boost of 20 /xg were given to those mice that showed anti-Lp(a) antibody production as verified by an ELISA assay of diluted mouse plasma taken from the plexus retro-orbitalis. The mice were killed 4 days after the final boost, and the spleens were removed aseptically.
Splenic lymphocytes were fused with Ag8 mouse myeloma cells and were distributed into 24-well plates (containing 1 ml/well RPMI-HAT medium and mouse peritoneal macrophages as feeder cells). Screening was begun when the colonies were 3 to 5 mm in diameter.
Screening by ELISA and Immunoblottlng
For an ELISA assay, 100 /xl of Lp(a) antigen, together with antimouse immunoglobulins at 2 to 5 /ig/ml in PBS (pH 7.4), was added to each of the 96-well Dynatech Immulon II ELISA plates. These were incubated overnight at 4°C. Before use, the plates were blocked (PBS, pH 7.4,1 % bovine serum albumin, 0.05% Tween 20, and 1 mg/ml dextran sulfate) for 30 minutes at room temperature.
Supernatants (100 /JL\) from the growing culture wells were transferred by pipette into duplicate wells and were allowed to react overnight at room temperature. Plates were washed thrice quickly with water, once with PBS + 0.05% Tween 20 for 10 minutes at 37°C, and again thrice with water. To each well was added 100 /J of goat antimouse immunoglobulins conjugated to alkaline phosphatase (Dakkopatts, Denmark) and diluted 1:1000 in PBTD. This was incubated for 5 hours at 37°C. Plates were washed as explained above, and 100 /xl of p-nitrophenyl phosphate (Sigma, FRG) in 0.05 M Na 2 CO 3 (pH 9.6) was added. After 30 minutes at 37°C, the plates were read visually and the positives were noted.
Positive wells were cloned by limiting dilution in HT-RPMI medium (without aminopterin). These secondary cultures were screened again by ELISA and cloned by limiting dilution. Recloned cultures were screened, selected, and grown as before in T25 and T75 flasks (Falcon, USA) when appropriate.
Mass Production and Purification of Monoclonal Antibody
Hybridomas were injected intraperitoneally in 12-weekold BALB/c mice that had been primed intraperitoneally 7 days earlier with 0.5 ml Pristane (Sigma, FRG). After 10 to 20 days, their asdtes fluid was obtained and the cells were removed by centrifugation at 400 g. The IgG fraction was purified from the mouse ascites fluid by using fast performance liquid chromatography (Pharmacia, Sweden). Ascites (up to a protein amount of 50 mg) was applied undiluted, but filtered through a 0.2 /xm membrane filter, on a Mono Q 5/5 anion exchange chromatography column after dialysis against 10 mM Tris (pH 7.4). IgG was obtained by elution with a 20 ml, 0 to 500 mM NaCI gradient in 10 mM Tris (pH 7.4). Purity was judged on the basis of 10% SDS-PAGE according to the method of Neville. 17
Characterization of Antibody
Antibody specificity was characterized by Western blotting of the purified Lp(a)-specific glycoprotein exactly as described above for the serum samples.
Further characterization was done by radioimmunoassay of the radiolabeled antigen. Lp(a) antigen was labeled with 12S I by the chloramine T method. The labeled antigen (about 200 000 cpm) was incubated with 200 AII of diluted culture supernatant (or ascites or purified antibody) for 2 hours at 37°C, then incubated with the second antibody (antimouse immunoglobulins) for 2 hours at 37°C, followed by an incubation with Protein-A Sepharose (Pharmacia, Sweden) for 30 minutes at room temperature. After a 5-minute centrifugation, the pellet was extensively washed with 10 mM Tris (pH 7.4) containing sodium desoxychclate, Triton X-100, SDS, and MgCI 2 , and this was counted in a gamma counter (LKB, Sweden).
Subisotyping was done with an ELISA kit from American Qualex. This assay consisted of a sandwich ELISA procedure, where the plate was coated with a capture antibody (goat antimouse immunoglobulins), followed by the unknown antibody sample (culture supernatant), followed by rabbit antisera against the various immunoglobulin subclasses, finally followed by a goat antirabbit, enzyme- Blot B Figure 1 . Samples from 15 different subjects were applied in two series on one gel as described under Methods. After the electrophoretic run, the gel was divided and the two parts were electroblotted. Blot A was developed by using the polyclonal antibody against Lp(a). Blot B was developed with the monoclonal antibody. The following Lp(a) phenotypes can be seen on the blots in the respective lanes: Lane 1, S1 + S2; Lane 2, B; Lane 3, S1; Lane 4, S1 +S2; Lane 5, S2; Lane 6, S2 + S3; Lane 7, S2; Lane 8, S1 + S3; Lane 9, S4; Lane 10, S4; Lane 11, S4; Lane 12, S1 +S2; Lane 13, B; Lane 14, B + S4; and Lane 15, F + S4. conjugated, detection system. All incubation steps had sufficient washing between procedures as previously described.
Results
Lp(a) phenotypes were identified in total plasma or serum by SDS-PAGE in horizontal slab gels followed by immunoblotting. Figure 1 shows two representative Lp(a) immunoblots: the upper one has been incubated with a polyclonal anti-Lp(a) antibody and the lower one, with our monoclonal antibody, MA 5', which came out to be an IgG 1 antibody by subisotyping. Samples from 15 different individuals were applied twice in two series on one gel. After the electrophoretic run, the gel was divided and the two parts were blotted as described. Comparing the two blots, it can be seen that the monoclonal antibody recognizes the same phenotypes as the polyclonal one does. Four different single-band phenotypes, as well as four different double-band phenotypes, are shown on the blots. The respective phenotypes are designated according to their relative electrophoretic mobility compared with that of apo B-100 ("F means faster than apo B-100, "B" means equal to apo B-100, and "S1-S4" are all slower than apo B-100 to different degrees). The position of apo B-100 was determined by using a specific anti-apo B antiserum as the first antibody in the immunoblot procedure (not shown). The "Pphenotype has so far been seen only in another group (patients of the local lipid clinic).
By using the new procedure, the Lp(a) phenotypes of 194 healthy individuals who served as blood donors were determined. The group consisted of 98 women (18 to 71 years old, mean age = 38.6, SD = 12.7) and 96 men (20 to 65 years old, mean age = 38.4, SD = 12.2). Their Lp(a) plasma concentrations were measured with an electroimmunoassay as described. The frequencies of the different phenotypes in this group are shown in Table 1 . The table gives also the Lp(a) plasma concentrations in the respective, single-band phenotypes. The nonparametric Kruskal-Wallis test showed a highly significant (p<0.001) difference between the Lp(a) lipoprotein concentrations of the respective Lp(a) phenotypes, thus confirming the recently found association of Lp(a) lipoprotein concentration with Lp(a) glycoprotein phenotype. 16 We assumed that Lp(a) phenotypes are controlled by five alleles that code for the B, S1, S2, S3, and S4 forms of Lp(a) glycoprotein and by a "0" allele, 16 and we calculated the allele frequencies ( Table 2 ). The introduction of a null allele is necessary to explain the occurrence of subjects with no detectable Lp(a), as well as the transmission of Lp(a) types in the family studies. 16 
Discussion
The described method easily enables Lp(a) phenotyping of up to 40 samples on one gel, in contrast to our hitherto used vertical gel system 16 which allowed only 13 samples on one gel. The new method is, therefore, ideally suited for screening large populations. A second great advantage is the simple casting procedure. In the vertical gel system, the soft, stacking gel gave rise to problems of leakage between the sample wells, which frequently resulted in These were calculated according to the method of Wiener et al. 23 and the correction formula of Dobson and Ikin. 24 smearing the Lp(a) bands on the blots. These problems in the vertical system could be overcome only by laborious tricks, e.g., treating the upper part of the glass plates (to which the stacking gel adheres) with Bind-Silane from LKB, Sweden (Menzel HJ, unpublished data). These problems do not exist in the horizontal system.
For Readers in the United States
The same phenotypes were demonstrated with the conventional polyclonal rabbit antisera, as well as with the monoclonal antibody MA 5' produced against the purified Lp(a)-specific glycoprotein, proving that high molecular weight bands are, indeed, Lp(a) glycoprotein. All genetic Lp(a) species were recognized equally well by the monoclonal antibody, MA 5'. This is in contrast to the reactivity of the monoclonal antibody, LHLP-1, developed by Duvic et al. 25 who used purified lipoprotein Lp(a) as the immunogen, which did not react with the reduced glycoprotein.
Our family studies showed that Lp(a) glycoprotein phenotypes are genetically controlled. 16 The frequency distribution for Lp(a) phenotypes determined here in a group of normal, unrelated blood donors is in keeping with this hypothesis. The Lp(a) allele frequencies that we calculated here are similar to those in a first group 16 with one notable exception. The frequency of the S4 allele, which is the one that is associated with the lowest Lp(a) plasma concentration, increased from 0.076 to 0.156 at the ex-pense of the Lp(a)° allele, which declined from 0.70 in the previous study to 0.60. This is due to the increased sensitivity of our new procedure. But still, in 37.6% of our probes, we found no detectable Lp(a) bands on the immunoblots. We do not know whether these are true negatives or whether they have small, though undetectable, amounts of Lp(a) in plasma. It is also possible that we lost some of the heterozygotes, especially when a faint S4 band was associated with a strong S1 or S2 band. More sensitive assays will be needed to answer these questions. Also, the association of the respective single-band Lp(a) phenotypes with Lp(a) plasma concentration, which was established in the previous study, was confirmed here in an unrelated group of subjects. The large variability of Lp(a) concentration within a °single-band phenotype," which is expressed in the standard deviation given in Table  1 , is partly due to the fact that these groups consist of homozogytes for the respective allele, as well as of heterozygotes with the null allele.
The method described in this paper will be helpful in performing large-scale genetic studies. Such studies are needed to confirm the genetic hypothesis, to determine Lp(a) glycoprotein phenotype frequencies in different populations, and to prove the postulated association of the genetic Lp(a) trait with atherosclerosis.
An association of Lp(a) lipoprotein concentration with myocardial infarction has been demonstrated in several case-control studies. 6 " 11 However, although under strong genetic control and, in general, rather constant individually, Lp(a) lipoprotein levels are known to be influenced by hormones, drugs, and disease states. 26 " 29 Hence, it has not yet been rigorously ruled out that elevated Lp(a) levels in myocardial infarction patients are the result, rather than the cause, of the disease. Prospective studies are needed to answer that question definitively. Our finding that the genetic Lp(a) protein type is associated with Lp(a) concentrations may allow us to circumvent this problem by comparing Lp(a) glycoprotein phenotypes in patients and controls. Moreover, our observation raises the challenging possibility that Lp(a) type, rather than concentration, is a risk factor for premature atherosclerosis. Studies on these aspects of Lp(a) glycoprotein polymorphism are now in progress in our laboratory, and we are using the technique described in this paper.
